The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.
Mylan Pharmaceuticals Inc. (a Viatris company) is conducting a recall at the retailer level of Methylprednisolone Tablets, USP 4mg, which is labeled as a Greenstone product and is packaged in a Dosepak, a blister card containing 21 tablets.

This lot is being recalled due to the incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.
This lot was distributed in the United States between Dec 05, 2025, and Dec 22, 2025.

To date, no report of adverse reactions associated with this lot have been received. The risk to the patient associated with this event is considered to be Medium.

Methylprednisolone tablets are indica ted in the following conditions:
Endocrine Disorders
Rheumatic Disorders
Collagen Diseases
Dermatologic Diseases
Allergic States
Ophthalmic Diseases
Respiratory Diseases
Hematologic Disorders
Neoplastic Diseases
Edematous States
Gastrointestinal Diseases
Nervous System
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate a ntituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement

PRODUCT: Methylprednisolone Tablets, USP 4mg

NDC NUMBER: 59762-4440-2

LOT NUMBER: LG7675

EXPIRY: Nov 2026